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SAŽETAK RADA 
Razvijena je i optimizirana HPLC metoda obrnute faze, za studiju stabilnosti 
farmaceutskih formulacija koje sadrže prostaglandin E1 i papaverin HCl kao glavne 
komponente. Studija stabilnosti bit će izvedena kroz sedam vremenskih točaka: t0 
(početna vremenska točka), te nakon jedan, dva, tri, četiri, pet, i konačno, šest mjeseci. 
Kromatografska separacija postignuta je na Alltima C18 5µ koloni (250 mm x 4,6 mm, 5 
µm) pri sobnoj temperaturi koristeći gradijentni protok pokretne faze. Pokretna faza A 
je mješavina 0,02 M fosfatnog pufera (pH 3.0) i acetonitrila (62:38 v/v). Pokretna faza B 
je mješavina 0,02 M fosfatnog pufera (pH 3.0) i acetonitrila (30:70 v/v). Protok 
pokretnih faza je 1,2 mL/min. UV detekcija izvedena je pri 205 nm. Metoda je validirana 
na specifičnost, linearnost, točnost, granice detekcije i kvantifikacije, te preciznost za dva 
glavna pika. Studija stabilnosti izvedena je za t0 (početna vremenska točka). 
 
Ključne riječi: farmaceutske formulacije, Prostaglandin E1, Papaverin, HPLC, UV, studija 
stabilnosti, razvoj metode 
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ABSTRACT 
An optimized reversed phase HPLC method, for the stability study of formulations 
containing prostaglandin E1 and papaverine HCl as main components, was developed. 
Stability study will be performed at seven time points: t0 (starting point), and then after 
one, two, three, four, five, and finally, six months. Chromatographic separations were 
achieved on an Alltima  C18 5µ column (250 mm x 4.6 mm, 5 µm) and maintained at 
room temperature using gradient elution. Mobile phase A was a mixture of a 0.02 M 
phosphate buffer solution (pH 3.0) and acetonitrile (62: 38 v/v). Mobile phase B was a 
mixture of a 0.02 M phosphate buffer solution (pH 3.0) and acetonitrile (30: 70 v/v). 
Mobile phases were pumped at a flow rate of 1.2 mL/min. UV detection was performed 
at 205 nm. The method was validated for specificity, linearity, accuracy, limit of 
detection, limit of quantification, and precision of the two main peaks. Stability study 
was performed for t0 (starting point). 
 
Key words: pharmaceutical formulations, Prostaglandin E1, Papaverine, HPLC, UV, 
stability study, method development 
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1. INTRODUCTION 
1.1 Prostaglandin E1 
1.1.1 Structure 
Prostaglandin E1 is a type of prostaglandin. Prostaglandins are a group of physiologically 
active lipid compounds having diverse hormon-like effects in animals. They are found in 
most animal and human tissues and are derived enzymatically from fatty acids. Every 
prostaglandin contains 20 carbon atoms, including a 5-carbon ring. It was firstly isolated 
from seminal fluid in 1935 by the Swedish physiologist Ulf von Euler, and also 
independently by M.W. Goldblatt. 1 
The synthetic variant of Prostaglandin E1 (PGE1) is known pharmaceutically as 
alprostadil2. Its structure can be seen in Figure 1. 
 
Figure 1 Structural formula of alprostadil 
 
1.1.2 Synthesis 
Alprostadil is biosynthesized from dihomo-γ-linolenic acid, which is an omega-6 fatty 
acid, in healthy humans without coronary artery disease or genetic disorders.3 
Simple and selective synthesis of alprostadil using an asymmetric Michael addition was 
developed by Hayashi and Umemiya. It was based on the Michael addition of butanedial 
to nitroalkene. This synthesis was performed in only three steps, including three 
isolations and three chromatographic purifications. It includes one-pot deprotection 
with metal-based reagents employed in the synthesis, which contain only nontoxic 
metals.4 5  
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1.1.3 Physicochemical properties 
The molecular formula of alprostadil is C20H34O5 (Mr=354.5 g/mol). IUPAC name is 7-
[(1R, 2R, 3R)-3-Hydroxy-2-[(1E, 3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic 
acid.6 It appears as a white to yellow crystalline solid. It is partly soluble in water, but 
soluble in organic solvents such as EtOH, MeOH or acetone. pKa value is 4.85. 7 
Alprostadil is considered toxic and may impair fertility.8 
 
1.1.4 Clinical use 
Prostaglandin E1 is used in the continuous treatment of erectile dysfunction because of 
its vasodilatory properties. Injectable forms are Edex and Caverject.9 Alprostadil (Prostin 
VR) is available as a generic and it usually comes in a formulation of two or three 
compounds. In this case it must be mixed by a compounding pharmacy, but is much less 
expensive. It should be kept refrigerated at 4 °C. 
Alprostadil is also used for critical limb ischemia, an advanced stage of peripheral artery 
disease10 and in maintaining a patent ductus arteriosus in newborns. 
Some of the adverse effects include accidental injury, cerebral or urethral bleeding, 
various kinds of pains, mainly in urethral area, fever, seizures and many more. 
 
1.1.5 Pharmacokinetics 
Alprostadil is considered today one of the drugs of choice, alone or in formulation with 
other drugs (vasoactive cocktails), for the diagnosis and treatment of erectile 
dysfunction. It is safe and easy to use. 
About 80 % of the drug is absorbed within 10 minutes of injection. Regarding 
distribution, 81 % is bound to albumin and about 55 % to alpha-globulin. About 80 % is 
metabolized in one pass through the lungs. It is also rapidly metabolized locally by 
enzymatic oxidation. Metabolites are extracted by the kidneys, about 90 % through 
urine in the first 24 hours. Half-life is between 0.5 and 10 minutes.11 
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1.1.6 Stability and dosage 
Prostaglandin E1 used in injections comes in as ethanol solution. It should be kept 
refrigerated at 2-8 °C, protected from light and excessive heat (>30°C). It should be 
stored in unopened foil pouches until use. In ethanol 10 mg/mL is stable for longer than 
6 months at -20 °C. Prostaglandins are generally unstable in aqueous acid or alkaline 
solutions, and alprostadil has a maximum stability between pH 6-7. When aqueous 
solutions are frozen, the prostaglandin may precipitate, but will usually redissolve on 
shaking or with sonification.12 13  
Alprostadil has a high chance to undergo physical and chemical degradation in the 
formulation and one of the main degradation products is prostaglandin A1 (PGA1). 
Therefore, it is imperative to develop an analytical method that will determine the 
possible existence of this molecule as well, with all other formulation substances. The 
chemical structure of PGA1 is shown in Figure 2. 
Therapeutical alprostadil doses vary from 5 to 50 µg/mL.14 Prescribing limits for adults 
in the case of treatment for erectile dysfunction are generally 60-65 µg/mL. 
 
Figure 2 Chemical formula of PGA1, degradation product of PGE1 
 
1.2 Papaverine 
1.2.1 Structure 
Papaverine is an opium alkaloid antispasmodic drug. While it is found in the opium 
poppy, papaverine differs in both structure and pharmacological action from opium 
alkaloids. It was discovered in 1848 by Georg Merck, a German chemist.15 
Papaverine is often used as a conjugate with hydrochloride. This way it is available for 
intramuscular, intravenous, rectal and oral administration. The nitrogen atom is 
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protonated and forms a strong hydrogen bond with the chloride ion. Distance between 
these two atoms is 3.01 Å. The isoquinoline ring is slightly non-planar but the benzene 
ring is planar within experimental error. The molecular structure of papaverine is of 
interest in gaining a better understanding of its pharmacological action on smooth 
muscle.16 
 
Figure 3 Structural formula of papaverine with its IUPAC nomenclature 
 
1.2.2 Synthesis 
Since the papaverine structure is relatively simple, it was soon prepared by synthesis. 
The first synthesis was accomplished by Pictet and Gams.17 Since the original synthesis a 
number of improvements have been made. 
 
1.2.3 Physicochemical properties 
Molecular formula of papaverine is C20H21NO4 (Mr=339.39 g/mol). IUPAC name is 1-(3,4-
Dimethoxybenzyl)-6,7-dimethoxyisoquinoline. It is sparingly soluble in water and 
slightly soluble in alcohol. Papaverine occurs as a white crystalline powder. In this thesis 
papaverine hydrochloride (C20H21ClNO4) is used. It is a colorless–lightly yellow liquid 
with relative molecular weight of 375.90 and pKa of 6.4. It can be examined in UV light at 
254 nm.18 19 
 
1.2.4 Clinical use 
Papaverine is an inhibitor for the relief of cerebral and peripheral ischemia associated 
with arterial spasm and myocardial ischemia complicated by arrhythmias. The main 
actions of papaverine are exerted on cardiac and smooth muscle. It acts directly on the 
 7 
 
heart muscle to depress conduction and prolong the refractory period. It relaxes various 
smooth muscles of the larger blood vessels. It increases cerebral blood flow because of 
its vasodilatory properties and therefore is used to treat problems resulting from poor 
blood circulation.20 One of the most common problems papaverine is used to treat, is 
erectile dysfunction, where it is used alone or in formulations. It is also used as a 
preventive to migraine headaches.21 22 
Some of the frequent side effects that come from papaverine treatments are ventricular 
tachycardia, vertigo, increased transaminase levels and others.23 
 
1.2.5 Pharmacokinetics 
Oral absorption of papaverine hydrochloride is found to be about 94 %. Volume of 
distribution is 0.99–1.52 L/kg and plasma protein binding is 87 %. Plasma half-life is 1.5 
– 2.2 h. It is metabolized by the liver and excreted in the urine in an inactive form. After 
intracavernosal injection, the peak plasma concentration is several times lower than 
after extracavernosal injection.24 25 
 
1.2.6 Stability and dosage 
Papaverine is stable under normal conditions, but it may discolor on exposure to light. It 
is not compatible with strong oxidizing agents and may be harmful if absorbed to skin.26 
Adult dosage is varying from 2.5 to 60 mg. A starting dose of 15 mg is recommended for 
most cases, although dosage adjustments should be made carefully.27 
 
1.3 Excipients 
Excipients are natural or synthetic substances formulated alongside the active 
ingredient or ingredients in a pharmaceutical formulation. They are included for 
purpose of long-term stabilization, bulking up solid formulations or enhancement of the 
active ingredient. They can facilitate drug absorption, reduce viscosity, enhance 
solubility, or can also be useful in the manufacturing process. Conclusively, they are an 
important part of drug formulations and therefore its quality, safety and functional 
standards are regulated by IPEC.28 
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1.3.1 Benzyl alcohol 
Benzyl alcohol is popular as a preservative in the cosmetic and pharmaceutical 
industries. It is soluble in water up to a concentration of about 4 %, but is usually used in 
a concentration of 0.9 % as a bacteriostatic preservative in multiple-dose vials of 
solutions or drugs for parenteral therapy. Benzyl alcohol solutions are microbiocidal 
(i.e., they have an antimicrobial effect) but are not regarded as a sanitizing agent, which 
would require a faster reduction of microorganisms. 
Benzyl alcohol is inexpensive, non-flammable, and can be disposed of relatively easily. 
Benzyl alcohol may be converted to benzaldehyde (and benzoic acid) by oxidation. 
Because benzyl alcohol is only partially soluble in water (4 g/100mL at room 
temperature) the reaction rate in water solutions is slow and no significant decrease in 
the benzyl alcohol concentration was observed during shelf life studies of the tested 
media. Benzyl alcohol will degrade some plastics, particularly at higher concentrations 
and temperatures.29  
 
1.3.2 Saline 
Saline is a solution of sodium chloride (NaCl) in water, usually in concentration of 0.9 % 
w/v NaCl in water. In this case it is referred to as normal saline, and it is used for 
parenteral (intravenous) application. pH of this solution ranges from 4.5 to 7.0.30 
 
1.4 High Performance Liquid Chromatography 
1.4.1  General 
Chromatography in general comprises all separation techniques in which analytes 
partition between a stationary and a mobile phase. In liquid chromatography, the mobile 
phase is a liquid, while the stationary phase can be a solid or a liquid immobilized on a 
solid. High-performance liquid chromatography comprises all liquid chromatographic 
techniques that require the use of elevated pressures to force the liquid through the 
packed bed of the stationary phase. Therefore it is also called high-pressure liquid 
chromatography. 
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The traditional form of liquid chromatography employed a polar adsorbent such as silica 
or alumina, and a nonpolar mobile phase based on hydrocarbons. Today, this type is 
called normal-phase chromatography. 
In reversed-phase chromatography, a nonpolar stationary phase is used in conjuction 
with polar, largely aqueous mobile phases. 70-80 % of HPLC applications utilize this 
technique. Most stationary phases are silica-based bonded phases. This kind of 
chromatography is popular nowadays thanks to its reproducibility and possibility of 
using a wide range of mobile phases.  
An HPLC instrument typically includes a pump, an injector, a column, detector and a 
computer with specific software which will provide the analyst with the desired data. 
The pump delivers a known flow and composition of the mobile phase through the 
column. The injector brings the sample to the mobile phase stream which carries it to 
the column and the detector generates a signal proportional to the amount of sample 
component emerging from the column and allowing quantitative analysis. A schematic 
view of an HPLC system is presented in Figure 4. 
 
Figure 4 HPLC system scheme31 
 
1.4.2 Isocratic and gradient 
In isocratic chromatography, all conditions and settings of the separation are held constant. 
On the other hand, in gradient chromatography one or more parameters are varied. In nearly 
all practical cases, only one parameter is varied. The most typical gradient is variation of the 
mobile-phase composition from low elution to high elution strength. 
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1.4.3 van Deemter equation 
The van Deemter equation is a simple equation describing the dependence of the HETP 
on the linear velocity. It assumes that the HETP is composed of three different, 
independent contributions, which simply add up and therefore form the observed 
curvilinear relationship: 
 
𝐻 = 𝐴 +
𝐵
µ
+ 𝐶µ 
[1] 
In this equation, A is called the Eddy diffusion and is a function of the size and 
distribution of the interparticle channels and other non-uniformities in the packed bed. 
B is inversely proportional to the linear velocity; it describes the molecular diffusion in 
the axial direction. C is resistance to mass transfer and is directly proportional to the 
linear velocity. µ is the average mobile phase velocity. The mobile phase velocity giving 
the optimal efficiency can be derived at the minimal plate height as depicted in Figure 
5.32 33 
 
Figure 5 van Deemter equation parameters dependent on H 
 
1.4.4 Reversed-phase HPLC 
1.4.4.1 Stationary phase 
The majority of reversed phase (RP) columns consist of alkyl derivatized silica particles 
which should not be used with aqueous bases as they will destroy the underlying silica 
particles. RP columns are usually used with an acidic mobile phase in the pH range 2-7. 
RP columns should be flushed with clean solvent after use to remove residual acids or 
buffers. 
For RP chromatography, the most popular type is octadecyl carbon chains (C18)-bonded 
to silica with over 600 columns commercially available. 34 
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1.4.4.2 Mobile phase 
Mixtures of water, buffers and organic solvents are used to elute analytes from a RP 
column. 35 The solvents have to be miscible with water and the most common organic 
solvents used are acetonitrile, methanol and tetrahydrofuran (THF). pH of the mobile 
phase can play a significant role on the retention of an analyte and can change the 
selectivity. 
 
1.4.4.3 Mechanism 
RP-HPLC operates on the principle of hydrophobic interactions, which play an important 
role in all processes in life science.36 
The binding of the analyte to the stationary phase is proportional to the contact surface 
area around the non-polar segment of the analyte molecule upon association with the 
ligand on the stationary phase. The retention can be decreased by adding a less polar 
solvent (methanol, acetonitrile) into the mobile phase to reduce the surface tension of 
water. 
Structural properties of the analyte molecule play an important role in its retention 
characteristics. In general, an analyte with a larger hydrophobic surface area (C-H, C-C 
and generally non-polar atomic bonds, such as S-S ) is retained longer because it is 
poorly interacting with the water in the mobile phase. On the other hand, analytes with a 
higher polar surface area (with polar groups such as -OH, -NH2, COO-, NH3+ in their 
structure) are less retained as they are better integrated into water. Such interactions 
are subject to steric effects in that very large molecules may have only restriced access 
to the pores of the stationary phase, where the interactions with surface ligands (alkyl 
chains) take place. This typically results in less retention. 
Retention time increases with the hydrophobic (non-polar) surface area of the analytes. 
Similary, organic compounds with single C-C bonds elute later than those with a double 
or triple bond, as they are shorther then single bonds respectively. 
 
1.5 Aim of the study 
Intracavernous formulations for treatment of erectile dysfunction are used widely in a 
modern medicine. It was introduced during the 1980s and has since become a common 
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form of therapy.37  Formulations studied in this thesis contain prostaglandin E1 
(alprostadil) at 20 and 10 μg/mL in association with papaverine HCl at 20 and 10 
mg/mL respectively. While alprostadil was the main compound to be subjected to 
physical and chemical degradation, its degradation and possible degradation products 
are correlated to the stability of the formulation. The low specific absorbance of 
alprostadil in the ultraviolet region, and the presence of high levels of papaverine and 
benzylalcohol in the formulation were the main difficulties for simultaneous 
determination of alprostadil, papaverine and benzylalcohol which is used as 
preservative in the formulations. 
The aim of this study is to develop a method that can be used to analyse formulations, 
with two different concentration profiles, overcoming the difficulties presented in the 
text above. The developed method has to be validated according to the ICH Harmonised 
Tripartite Guidelines. 
Different compositions of mobile phase and different values of pH were studied to find 
the best chromatographic conditions for the analysis of these formulations. A sensitive, 
selective, linear, precise and accurate reversed-phase high-performance liquid 
chromatographic (RP-HPLC) method was developed. 
Finally, stability of the formulation will be studied at seven different time points. 
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2. MATERIALS AND METHODS 
2.1 Instrumentation 
Most analyses were performed on a Dionex HPLC system (Sunnyvale, CA, USA) that 
consisted of a LPG-3400A HPLC pump, an ASI-100 autosampler equipped with a 100 µL 
syringe and a LINEAR UVIS 200 UV detector which was operated at 205 nm. The dwell 
volume of the system was 0.4 mL. Part of the analyses was performed on a Merk-Hitachi 
(Darmstadt, Germany) that consisted of a L-6200 Intelligent pump, an Elite LaChrom L-
2200 autosampler equipped with a 100 µL syringe and an Elite LaChrom L-2400 UV 
detector which was operated also at 205 nm. The dwell volume of that system was 4.0 
mL. For data processing and acquisition, Chromeleon software version 6.8 from Dionex 
(Sunnyvale, CA, USA) was used. The pH measurements were performed on a 691 
Metrohm pH meter (Herisau, Switzerland). A Milli-Q water purification system 
(Millipore, Bedford, MA, USA) was used to further purify demineralized water. 
Chromatographic separations were achieved on an Alltima  C18 5µ column (250 mm x 
4.6 mm, 5 µm) from Alltech Associates, Inc. (Nicholasville, Kentucky, USA) All prepared 
mobile phases were degassed by purging with helium. The Dionex instrumentation is 
shown in Figure 6. The Alltima column is shown in Figure 7. 
 
Figure 6 Dionex pump and autosampler 
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Figure 7 Alltima C18 column 
 
2.2 Chemicals and reagents 
HPLC gradient grade acetonitrile was from Fisher Scientific (Leicestershire, UK). 
Potassium dihydrogen phosphate and phosphoric acid were from Merck (Darmstadt, 
Germany). 
2.3 Samples and reference substances 
Commercial samples of alprostadil were obtained from Pfizer as the commercial drug 
Prostin® VR, 0.5 mg of alprostadil per mL of ethanol as an injectable solution. 
Papaverine HCl ampules were obtained in a concentration of 100 mg/3 mL as in 
injectable solution. Benzyl alcohol came as a 2 mL ampule and a 0.9 % sodium chloride 
solution Viaflo bag was from Baxter. 
 
2.4 Experimental part 
2.4.1 Sample preparation 
Stability study and method validation presented in this thesis were developed for two 
formulations, both consisting of alprostadil, papaverine HCl, benzyl alcohol and saline 
solution. Concentrations of main components in the formulations were different for each 
of the two formulations as can be seen in Table 1. 
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Table 1 Formulations used for stability study and method development 
Formulation 1 Prostin VR 20 µg 
 
Papaverine HCl 20 mg 
 
Benzyl alcohol 9 mg 
 
Saline to 1 mL 
   Formulation 2 Prostin VR 10 µg 
 
Papaverine HCl 10 mg 
 
Benzyl alcohol 9 mg 
  Saline to 1 mL 
 
As a reference for formulation 1, Prostin VR was diluted with MilliQ water or saline 
solution to obtain an alprostadil concentration of 20 µg/mL which was used in the 
analytical method. For the determination of alprostadil, formulation 1 was injected as 
such. Papaverine ampules were diluted with MilliQ water in order to get a drug 
formulation concentration of 20 mg/mL. However, due to a very large peak area, this 
concentration had to be 1000 times diluted with MilliQ water to obtain a test 
concentration that was used to perform analysis. For the determination of papaverine, 
formulation 1 was also diluted 1000 times. The same way of sample and reference 
preparation can be applied to formulation 2. 
Injection volume used in the method is 50 µL.38 However, in few cases, 100 µL was used. 
Reason for that will be explained further in the thesis. 
 
2.4.2 Current European Pharmacopoeia method for individual drugs 
2.4.2.1 Prostaglandin E1 
With similar column properties as used in this thesis, the Pharmacopoeia method is the 
following: it consists of two mobile phases, A and B. Mobile phase A is prepared by 
dissolving 3.9 g of KH2PO4 in water and diluting it to 1000.0 mL with the same solvent. It 
needs to be adjusted to pH 2.5 with a 2.9 g/L solution of phosphoric acid (around 600 
mL). 740 mL of the buffer solution and 260 mL of acetonitrile are required for mobile 
phase A. Mobile phase B is prepared the same way, but solvents are added in a different 
ratio. 200 mL of the buffer solution and 800 mL of acetonitrile are required for mobile 
phase B. Flow rate is 1 mL/min with 20 µL loop injector and detection wavelength 200 
nm. Retention time of alprostadil with this system is about 63 min.39 
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2.4.2.2 Papaverine 
For papaverine similar column properties as mentioned above for alprostadil are used. 
Mobile phase A is 3.4 g/L solution of KH2PO4 adjusted to pH 3.0 with dilute phosphoric 
acid. Mobile phase B is acetonitrile, and C is methanol. Gradient method for papaverine 
included in the Pharmacopoeia is shown in Table 2. 
 
Table 2 Gradient method for papaverin HPLC analysis 
Time Mobile phase A Mobile phase B Mobile phase C 
 (min) (per cent V/V/V) (per cent V/V/V) (per cent V/V/V) 
0 - 5 85 5 10 
  5 - 12 85 →60 5 10 → 35 
12 - 20 60 5 35 
20 - 24 60 →40 5 → 20 35 → 40 
24 - 27 40 20 40 
27 - 32 40 → 85 20 → 5 40 → 10 
 
With this composition of mobile phasest the flow rate used is 1 mL/min, detection 
wavelength is 238 nm and injection volume is 10 µL.40 
 
2.4.3 Chromatographic conditions 
The separation was performed on an Alltima C18 column (250×4.6mm; 5 μm particles) 
with a gradient method and a mixture of phosphate buffer (KH2PO4 0.02 M, pH 3) and 
acetonitrile as a mobile phase. The mobile phase ratio was variable: 0-11 min and 19-29 
min with a (62:38, v/v) mixture of phosphate buffer and ACN, and from 12-18 with a 
(30:70, v/v) mixture. The mobile phases were manually mixed. The injection volume 
was 50 μl. Samples were held at a temperature of 4 °C in the autosampler with analysis 
performed at room temperature. Mobile phase flow rate was 1.2 mL/min for the 
duration of analysis. Wavelength used was 205 nm. 
 
2.4.4 Procedures for method validation 
Validation was performed for the main peaks, alprostadil and papaverine, for specificity, 
linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), precision, 
repeatability and solution stability. 
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2.4.4.1 Specificity 
Specificity was shown by examining potential interferences between formulation 
components like benzyl alcohol, alprostadil and papaverine and their degradation 
products. 
 
2.4.4.2 Degradation studies 
Forced degradation studies were performed on alprostadil and papaverine in order to 
demonstrate the selectivity and stability indicating capability of the proposed method. 
Analytes were exposed to a temperature of 80 °C for 24 hours. Samples were then 
analyzed by the proposed method. 
 
2.4.4.3 Sensitivity 
The limit of detection (LOD) and limit of quantification (LOQ) for both alprostadil and 
papaverine were determined at a signal-to-noise ratio of 3 and 10, respectively.  
 
2.4.4.4 Linearity 
Linearity responses of the detector for alprostadil and papaverine were examined 
around the test concentrations (20 µg/mL for both analytes). Percentages were 120 %, 
100 %, 80 %, 60 % and 50 % of the test concentration corresponding to concentrations 
of 24, 20, 16, 12, 10 µg/mL respectively. 
 
2.4.4.5 Accuracy 
The accuracy was calculated by comparing numerical values of peak areas given by the 
main peaks in spiked blanks and their reference solution peaks with an acceptance 
criterion between 98.0 and 102.0 %. 
 
2.4.4.6 Precision 
Repeatability was determined by injecting the two formulation solutions six times. 
Alprostadil concentrations in the formulations were 20 µg/mL and 10 µg/mL 
respectively while concentrations of papaverine were 20 mg/mL and 10 mg/mL. Test 
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solutions for alprostadil were injected as such. Test formulations for papaverine were 
diluted 1000 times with MilliQ water, giving a test concentrations of 20 and 10 µg/mL. 
The percentage RSD was calculated for the two main peaks in both formulations. 
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3. RESULTS AND DISCUSSION 
3.1 Development and optimisation of the analytical method 
The main difficulty in the development of the method for determination of alprostadil 
and papaverine in the formulation simultaneously is the low specific absorbance in the 
UV zone and low concentration of alprostadil. That, together with the high 
concentrations of papaverine and benzyl alcohol, made the proper separation of the two 
main peaks challanging, but in the end, achiveable. 
UV detection was chosen instead of other detection modes cited in the literature because 
of its robustness and precision.  
Levels of papaverine and benzyl alcohol were high compared to alprostadil, and 
therefore saturating the detector when no dilution was performed. The separation of 
alprostadil depended largely on the wideness of the papaverin and benzyl alcohol peaks. 
Optimization of chromatographic conditions was made and good resolution with 
symmetrical peak shapes was achieved. Analysis time is relatively short. 
 
3.1.1 Wavelength selection 
The UV detector could only select one wavelength at a time, and it was set to 205 nm, 
which is found to be the optimal wavelength for alprostadil determination based on the 
signal to noise ratio. Low specific absorbance of alprostadil was preventing the usage of 
higher wavelength settings. 
 
3.1.2 Mobile phase 
Composition of the mobile phase and its pH value are both important factors in the 
development of the analytical method. Chosen organic solvent was acetonitrile (ACN). 
Its cut-off value is at 190 nm. So it is compatible with detection at 205 nm. Different 
values of pH and proportions of ACN and phosphate buffer have been tested. pH 3.0 was 
selected as it gave good resolution between the main peaks. pH 3.5 and 4.0 were tested 
as well, but with pH 3.0 the separation was optimal. Proportions of ACN under 40 % 
allowed a good resolution between the peaks of papaverine, benzyl alcohol, and 
alprostadil. Proportions above that value were not suited for a good separation and lead 
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to coelution of papaverine and benzyl alcohol. Proportions of ACN under 30 % were not 
suited because they affected elution times, and therefore would make the analysis 
longlasting. The proportion of 38 % ACN and 62 % phosphate buffer (0.02 M) lead to a 
good separation and short retention times for the main peaks with the alprostadil peak 
eluting around 11 min.  
However, with degradation studies, analysis time was prolonged to 29 minutes. A 
gradient method by changing the mobile phase composition was used to improve the 
analysis. Mobile phase A is as described above (38 % ACN and 62 % phosphate buffer 
0.02 M). Composition of mobile phase B was 70 % of ACN and 30% of phosphate buffer 
0.02M after testing several different compositions. Due to possible precipitation of the 
buffer, compositions above 70 % of ACN were discarded. Compositions under 70 % ACN 
were suitable for the method, but in the end 70 % of ACN was chosen because of an 
optimal analysis time. In table 3, the gradient used in this method is shown. 
 
Table 3 Method - mobile phase gradient 
Time Mobile phase A Mobile phase B 
 (min) (per cent V/V) (per cent V/V) 
0 - 11 100 0 
11 - 12 100 → 0 0 → 100 
12 - 18 0 100 
18 - 19 0 →100 100 → 0 
19 - 29 100 0 
 
3.1.3 Flow rate 
In order to shorten the analysis time, but keep the flow rate in the optimal range, a flow 
of 1.2 mL/min was used. 
 
3.2 Method validation 
3.2.1 Specificity 
The method is specific enough to have a good separaton between alprostadil peak 
(around 11th minute) and partly co-eluted papaverine and benzyl alcohol peaks 
(between 3rd and 6th minute) which can be seen in Figure 8. It is also specific enough for 
a good separation between papaverine and benzyl alcohol peaks if diluted 1000 times 
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with MilliQ water. This can be seen in Figure 9. Detection of alprostadil in this case is not 
possible due to its very small concentration after dilution. 
 
 
Figure 8 Chromatogram of alprostadil reference (1) and the formulation injected as such (2) 
 
 
Figure 9 Chromatogram of papaverine reference (1) and the formulation [1:1000 diluted] (2) 
3.2.2 Degradation studies 
Chromatogram obtained under stress conditions for alprostadil is shown in Figure 10. 
Both alprostadil and papaverine samples were exposed to a temperature of 80 °C for 24 
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hours. Alprostadil sample chromatograms after exposure reveal new peaks that are 
presumed to be degradation products. After 7 hours of exposure, the alprostadil peak 
area was considerably decreased and after 24 hours the alprostadil peak was completely 
gone. The papaverine sample chromatogram after degradation study did not reveal new 
peaks related to degradation products. It remained stable, although a small peak area 
decrease was noted. From chromatograms 2 and 3, shown in Figure 10, it is clear why a 
gradient program was introduced. This adjustment was necessary because degradation 
peaks appeared around 26 and 30 min if no gradient was applied. With gradient, they 
appeared around 19 minutes (chromatogram 3). After their elution, the mobile phase 
composition returns to its starting conditions. That gives 29 minutes as total analysis 
time for this method.  
 
Figure 10 Chromatograms of alprostadil degradation studies: alprostadil sample before exposure 
to 80 °C, isocratic (1); alprostadil sample after 7h of exposure to 80 °C, isocratic (2); alprostadil 
sample after 24 hours of exposure to 80 °C, gradient (3) 
 
3.2.3 Sensitivity 
Limit of detection and limit of quantification were determined. For alprostadil, LOQ 
calculated was 240 ng/mL, with an injection volume of 50 µL corresponding to a signal-
to-noise ratio of 10. LOD in this case was 100 ng/mL, with an injection volume of 50 µL 
corresponding to a signal-to-noise ratio of 3. 
 23 
 
For papaverine the LOQ calculated was 40 ng/mL, with an injection volume of 50 µL 
corresponding to a signal-to-noise ratio of 10. LOD in this case was 12 ng/mL, with an 
injection volume of 50 µL corresponding to a signal-to-noise ratio of 3. 
As mentioned before, two different instrumentations, on which analyses were 
performed, were used in this thesis. Firstly, method development was performed on a 
Merk-Hitachi system (Darmstadt, Germany). Problem occurred when LOQ and LOD for 
papaverine were in the process of validation. It was found that there was a system peak 
co-eluting with the papaverine peak. Therefore LOQ and LOD for papaverine could not 
be determined. Many attempts were taken in order to separate the co-eluted peaks, but 
in the end they were all unsuccessful. Solution was to change the system and from that 
point, all analyses and validation procedures were performed on a Dionex HPLC system 
(Sunnyvale, CA, USA). Validation procedures already validated on the Merck-Hitachi 
system were validated again on the Dionex system. 
 
3.2.4 Linearity 
Linear calibration curves between peak area and concentration were obtained for both 
alprostadil and papaverine. Alprostadil regression data analysis shows that R2 value is 
0.9999 (Figure 11). The 95 % confidence interval of the intercept does not contain zero, 
which is considered unreliable in statistical terms. However, with the standard error 
being extremely small, the interval is also small, and the fact that it does not contain zero 
is acceptable. When the intercept is expressed versus the peak area of 100 % 
concentration, it amounts to 1.7 % which is lower than the generally accepted limit of 5 
%. The residual plot shows no trend (Figure 12). Therefore, linear correlation can be 
considered good and satisfying. 
Papaverine regression data analysis shows R2 value of 0.9998 (Figure 13). The 95 % 
confidence interval in this case contains zero which shows good linear correlation. The 
residual plot obtained from data analysis is shown in Figure 14.  
 24 
 
 
Figure 11 Calibration plot showing linearity of alprostadil 
 
 
Figure 12 Residual plot for alprostadil 
 
 
Figure 13 Calibration plot showing linearity of papaverine  
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Figure 14 Residual plot for Papaverine  
 
3.2.5 Accuracy 
Percentages of recovery were determined by comparing spiked analyte peak area mean 
gained from three injections, and reference peak area mean, also from three injections. 
Acceptance criteria were expressed in percentages from 98.0-102.0 %. Two 
formulations have been tested, with different concentrations of main components. 
Alprostadil and papaverine recovery for both formulations can be seen in Tables 4 and 
5. 
Table 4 Recovery of alprostadil 
Alprostadil 
Sample mean 
[Mau*min] 
Reference mean 
[Mau*min] 
Recovery 
(%) 
Formulation 1 
8.962 9.014 99.4 
Inj. Vol (50µL ) 
Formulation 2 
7.066 7.016 100.7 
Inj. Vol (100 µL ) 
 
Table 5 Recovery of papaverine 
Papaverine 
Sample mean 
[Mau*min] Reference mean [Mau*min] 
Recovery 
(%) 
Formulation 1 84.815 85.532 99.2 
Formulation 2 87.692 86.283 101.9 
 
Injection volume used for this method is, as stated before, 50 µL. However, 100 µL 
injection volume was used for accuracy validation of alprostadil in formulation 2. 
Formulation 2 contains 10 µg/mL of alprostadil, which is two times less then what 
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formulation 1 contains. This way similar peak areas should be obtained. As mentioned 
before, peak areas and concentrations of alprostadil in both formulations are very small. 
Therefore, accuracy test for alprostadil in formulation 2 was performed in a way to get 
the same peak area as in formulation 1. This way, for both formulations, peak areas 
already validated in linearity test were obtained.  
All accuracy tests follow acceptance criterion and are in the range between 98.0 and 
102.0 %. However, with 100 µL injections used for accuracy validation of alprostadil in 
formulation 2 a decrease in peak area, compared to formulation 1, for both sample and 
reference is noticed. Since the device on which analysis were performed was validated, it 
is concluded that the reason for such a deviation lies in different amounts of excipients 
present in each of the formulations, specifically saline. Main components are held in a 
different environment and this could affect the difference in peak areas when it concerns 
alprostadil since this component is sensitive.  
To confirm conclusions mentioned above alprostadil reference was tested in both water 
and saline as dissolution media. Difference in peak areas was noted and results can be 
seen in Table 6. 
Table 6 Recovery of alprostadil in different dissolution media 
  
Area 
[Mau*min] 
Recovery 
(%) 
Reference Saline 8.365 
97.82 
Reference Water 8.551 
 
3.2.6 Precision 
The % RSD values for precision were <2 %, which confirms that the method is 
sufficiently precise. Results can be seen in Tables 7 and 8. For alprostadil presented in 
formulation 2, the same precision validation principle was used as mentioned in 4.2.5 for 
accuracy. 
Table 7 Precision validation of alprostadil 
Alprostadil 
Sample mean 
[Mau*min] SD RSD (%) 
Formulation 1 
8.927 0.056 0.62 
Inj. Vol. (50 µL) 
Formulation 2 
7.055 0.034 0.48 
Inj. Vol. (100 µL) 
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Table 8 Precision validation of papaverine 
Papaverine Sample mean [Mau*min] SD RSD (%) 
Formulation 1 86.442 0.452 0.52 
Formulation 2 88.329 0.329 0.37 
 
3.3 Stability study 
Stability study of formulation 1 presented in Table 9 will be tested in the time span of 
several months, at seven different time points. Formulation was prepared as one 
solution. Part of the solution was filled in syringes (1 mL) and part in vials (5 mL). 
Stability study was conducted on both vial and syringe solutions.  
Stability study samples and references preparation will be carried out the same way as it 
was during method validation. Percentages of recovery will be determined by 
comparing spiked analyte peak area mean gained from three injections, and reference 
peak area mean, also from three injections. It will be conducted for both of the main 
compounds in the formulation.  
 
Table 9 Formulation for stability study 
Formulation 1 Prostin VR 20 µg 
 
Papaverine HCl 20 mg 
 
Benzyl alcohol 9 mg 
 
Saline to 1 mL 
 
3.3.1 Starting point (t0) 
Results obtained for starting point (t0) of stability study can be seen in Tables 10 and 11. 
Results indicate that developed analytical method is suitable for stability testing at this 
time point and that method is comparable between syringe and vial solutions. Recovery 
criterion was expressed in percentages which should be in range from 95.0 to 105.0 %. 
Relevant chromatograms are shown in Figures 15 and 16. 
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Table 10 Recovery of alprostadil (t0) 
Alprostadil 
Sample mean 
[Mau*min] 
Reference mean 
[Mau*min] 
Recovery 
(%) 
Vial 
8.409 8.365 100.53 
Inj. Vol (50µL ) 
    
Alprostadil 
Sample mean 
[Mau*min] 
Reference mean 
[Mau*min] 
Recovery 
(%) 
Syringe 
8.448 8.365 101.00 
Inj. Vol (50µL ) 
 
 
Figure 15 Stability study t0 chromatogram: vial sample (1); alprostadil reference (2); syringe 
sample (3) 
 
Table 11 Recovery of papaverine (t0) 
Papaverine 
Sample mean 
[Mau*min] 
Reference mean 
[Mau*min] 
Recovery 
(%) 
Vial 
86.381 85.817 100.66 
Inj. Vol (50µL ) 
    
Papaverine 
Sample mean 
[Mau*min] 
Reference mean 
[Mau*min] 
Recovery 
(%) 
Syringe 
81.124 83.208 97.50 
Inj. Vol (50µL ) 
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Figure 16 Stability study t0 chromatogram: papaverine reference (1); vial sample (2); syringe 
sample (3) 
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4. CONCLUSION 
An optimized reversed phase HPLC method, for the stability study of formulations 
containing prostaglandin E1 and papaverine HCl as main components, has been 
developed. The method is specific, linear, accurate, sensitive, and precise when it comes 
to the two main components. The method will be used to check the stability of 
alprostadil – papaverine formulation 1 over several months. Starting time point (t0) has 
been tested for stability and results obtained can indicate that developed analytical 
method is suitable for such a test at starting time point. Following stability study tests 
will show weather the method will continue to provide a good base for stability study of 
given formulation. 
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